Inpart’s Post

As the payer, PBM, and trade ecosystems continue to evolve and react to regulatory and market forces, it's increasingly important for Life Science companies to adopt digital-first solutions across the market access life cycle. In this piece we detail how companies can enhance their pre-deal analytics through interoperable single-view digital market access solutions that directly impact access, GTN, and patient acquisition cost.

In the second piece in our series on digital innovation, we detail how Life Science companies adopting innovative digital-first pre-deal analytics solutions are taking their market access strategies and excelling with their launches and throughout the product lifecycle. Read to learn about how traditional approaches lead to missed opportunity and what to look for when adopting a digital market access ecosystem, and reach out to learn how our clients are innovating through our platforms. https://lnkd.in/gDWWrZUG

I am excited to share our second whitepaper in our series which looks at the importance of automated, real-time pre-deal analytics for Life science customers. Interested in leveraging advancements in AI & ML to automate your pre-deal contracting analytics to support internal teams? Please read to learn more.

Our upcoming webinars offer a deep-dive into the top-5 digital collaboration trends for Pharma. Discover how to leverage virtual platforms for more impactful KOL and patient interactions. Save your spot: https://hubs.la/Q02jtpmy0 #DigitalHealth #PharmaEducation

📣 Last chance to register! Join experts from IQVIA for MI insights, practical strategies, and illuminating real-world examples in this free webinar. Register now: https://ow.ly/3GMk50T1uvJ. How can you equip Medical Information (MI) teams with the resources they need to successfully navigate a complex and continually evolving pharma landscape? Learn more about how MI can leverage leading-edge technology tools to meet the challenges of both globalization and increasingly sophisticated MI inquiries.

I am putting together a presentation titled “The Link Between Science & Commercial Strategy for Pre-IPO Pharma Success.” One of the suggested slides is on the topic of best practices early companies engage in to overcome common pitfalls in their pursuit of success. Some of the successful behaviors I listed include - 📈 Understanding how innovation will translate into market success. Great science does not guarantee commercial success.  ⚠️   Factoring the technical risk of FDA approval into strategic planning. Too often, companies      miss key information the FDA is communicating. 🔂 Developing key strategies early based on commercial analytics. Commercial represents a lot more than just sales and marketing.  ⚙️  Having the tools and processes for considering a wide variety of strategic options and risks. All too often companies treat forecasts as number generators vs. strategy assessment tools. Speed to market is rarely a winning strategy. 🗣  Creating dialogue between commercial and clinical leads. A lack of organizational alignment is detrimental to corporate success. Now it’s your turn! Let's start a conversation and learn from each other as we navigate the challenges and opportunities that come with bringing innovative therapies to market. Share your thoughts and experiences in the comments below and let's collaborate for pre-IPO pharma success. #IlluminationStrategyGroup #PharmaInnovation #Teamwork

At #futurepharma, we give you everything you need to make the most of your 10+ hours of dedicated networking time with decision makers ready to invest in your solution. How else can your company stand to benefit by sponsoring Future Pharma 2024? Learn more here: https://bit.ly/3Zncx3Q #digitalhealth #healthcareinnovation

Learn how to gain a competitive edge through patient-reported outcomes (PROs). Partnering lead, Jolanda, discusses the potential benefits of PROs for pharma partners. Discover how these measures can enhance #ClinicalTrials and #ProductDevelopment: https://buff.ly/4dsxr8n Sign up for updates delivered straight to your inbox! Gain real-life insights from our patient experts, discover the benefits of patient-led design, and explore patient-centered go-to market solutions: https://buff.ly/3UPc8Xb #HealthcareInnovation #MiniCommunities

🌟 Introducing Clairvoyance: The Future of Decision Analytics and Forecasting! 🌟 Unlock the potential of your project portfolio management with Clairvoyance, the pioneering platform tailored for precision and innovation. This tool is designed to transform your decision-making process by providing accurate insights and forecasts that ensure your projects stay ahead of the curve. 🔍 Why Clairvoyance? 1. Precision Insights: Make smarter decisions based on accurate data. 2. Enhanced Forecasts: Predict project outcomes with greater confidence. 3. Industry-Specific: Tailored for pharmaceutical R&D. Explore the future of data-driven decision-making with Clairvoyance. Visit i2e Consulting to learn more: https://lnkd.in/gShCV4VJ #DecisionAnalytics #Forecasting #ProjectManagement #Pharmaceuticals #Innovation i2e Consulting

Uplifts in revenue, brand reputation, talent acquisition and clinical trial outcomes are just some benefits biopharma companies are seeing by prioritizing sustainability. Below addresses the 'whys' and 'hows' of advancing healthcare and impacting the bottom line through sustainability. Take a look for yourself and and find out more here: https://cytiva.link/58xnx